Clinical trials: Nonalcoholic Fatty Liver
Fatty Liver Disease
Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity
The non-invasive evaluation of liver steatosis and fibrosis with FibroScan is a routinely procedure in clinical practice for people with obesity.
- Trial name
- MASLD (NCT06720766)
- Testing
- FibbroScan and biopsy
- Where
- China
- Volunteers
- 565 people
- Sponsor
- The Third People's Hospital of Chengdu
Nonalcoholic Steatohepatitis (NASH)
A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension
This is a randomized, blinded, placebo-controlled study of Efimosfermin in obese participants at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH), with a single arm open-label extension.
- Trial name
- NCT04880031
- Testing
- Efimosfermin
- Where
- 48 sites in United States
- Volunteers
- 231 people
- Sponsor
- GlaxoSmithKline
NAFLD, NASH
THE FRENCH NATIONAL NAFLD COHORT (FRench pAtients With MEtabolic Steatosis)
The main objective of this cohort study is to determine genetic, clinical biologic and metabolic factors associated with patient heterogeneity in regards to severity of NAFLD at diagnosis as well as during the clinical course.
- Conditions
- NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis
- Trial name
- FRAMES (NCT04925362)
- Testing
- Biological specimens, Additional visit
- Volunteers
- 900 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Nonalcoholic Fatty Liver Disease, HIV
Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy
A subset of patients with NAFLD that have not been extensively studied are those infected with human immunodeficiency virus (HIV). Currently, there is no FDA approved treatment for NAFLD or NASH.
- Trial name
- ARRIVE (NCT02684591)
- Testing
- Aramchol
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Non-Alcoholic Fatty Liver Disease, Obesity
Influence of the Diversity and Composition of the Microbiota in the Development of Pediatric Fatty Liver
The objectives of the present study are: 1) to identify the intestinal and salivary microbiota associated with the presence and severity of hepatic steatosis in children (Study I: case-control study), and 2) to develop a…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obesity, Metabolic Syndrome
- Trial name
- MicroKid (NCT04575506)
- Testing
- Multidisciplinary intervention program
- Where
- 2 sites in Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Universidad Pública de Navarra
Non-alcoholic Fatty Liver Disease
Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis
The aim of study was to evaluate the effect of helicobacter pylori eradication on liver fat content, liver function tests, lipid profile, homeostasis model assessment-IR (HOMA-IR) index, and anthropometric measurements (body mass…
- Trial name
- NCT01654549
- Testing
- H.pylori eradication
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Tehran University of Medical Sciences
Obesity, Weight Loss
Weight Loss in Adults With Obesity Using a Combination of Low Energy Diet, Group Treatment and Intragastric Balloon
In Sweden, approximately 1.3 million adults have obesity. Obesity decreases quality of life (QoL) and increases the risk of diseases such as type 2-diabetes, non-alcoholic fatty liver disease (NAFLD), cancer and cardiovascular…
- Conditions
- Obesity, Weight Loss, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT04230655
- Testing
- Low energy diet using meal replacements, CBT-based group treatment, Intragastric balloon
- Where
- Sweden
- Volunteers
- 110 people
- Sponsor
- Region Örebro County
Non-alcoholic Steatohepatitis (NASH)
A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with NAFLD and NASH.
- Trial name
- NCT02927314
- Testing
- CF102
- Where
- 3 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Can-Fite BioPharma
Non-Alcoholic Fatty Liver Disease
Investigation of Synbiotic Treatment in NAFLD
Non-alcoholic fatty liver disease (NAFLD) is a liver condition in which fat builds up in the liver not caused by alcohol. The liver is an organ that is not designed to build up fat.
- Trial name
- INSYTE (NCT01680640)
- Testing
- Synbiotic, Maltodextrin
- Where
- United Kingdom
- Volunteers
- 104 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Fatty Liver
The Effect of a Probiotic on Hepatic Steatosis
Non-alcoholic fatty liver disease (NAFLD) is an accumulation of fat and fibrous tissue in the liver. It is the most common cause of chronic liver disease in the United States.
- Trial name
- NCT00099723
- Testing
- VSL#3
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- VSL Pharmaceuticals
Nonalcoholic Fatty Liver Disease
Effect of Treatment With Insulin Sensitizer on Arterial Properties, Metabolic Parameters and Liver Function in Patients With Nonalcoholic Fatty Liver Disease
Abstract Background: Insulin resistance has an important role in the development of nonalcoholic fatty liver disease (NAFLD) and is involved in both pathological processes: hepatic steatosis and atherosclerosis.
- Trial name
- NCT01084486
- Testing
- Metformin
- Where
- Israel
- Sponsor
- Wolfson Medical Center
Non Alcoholic Fatty Liver, Obesity
Effect of Probiotics or Berberine in Hepatic Steatosis Markers, Cardiometabolic and Microbiotic Profile in NAFL.
Effect of oral selected Probiotics (PRO) and/or Berberine (BBR) supplementation on hepatic steatosis markers, cardiometabolic profile, and gut microbiota profile in the non-alcoholic fatty liver (NAFL) - a randomized double-blind…
- Trial name
- NCT05523024
- Testing
- Probiotic, Berberine, Probiotc and Berberine
- Where
- Poland
- Volunteers
- 140 people
- Sponsor
- Poznan University of Medical Sciences
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Conditionally Increased Output (CIO) Enhanced Ultrasound System
This study aims to assess possible bioeffects that may be caused by the use of shear wave elastography (SWE) with conditionally increased acoustic output pressure (CIO).
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fatty Liver
- Trial name
- NCT05792423
- Testing
- GE ultrasound system with increased acoustic output settings
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic…
- Trial name
- RESOLVE-IT (NCT02704403)
- Testing
- Elafibranor
- Where
- 326 sites in United States, Argentina and 23 more
- Volunteers
- 2,157 people
- Sponsor
- Genfit
Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease
Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease
This study is a randomized, non-blinded clinical trial specifically designed to assess the initial feasibility and efficacy of SGLT2 inhibitors in treating NAFLD among adults diagnosed with type 2 diabetes.
- Trial name
- NCT06218342
- Testing
- Henagliflozin, Background medication
- Volunteers
- 156 people
- Sponsor
- Sir Run Run Shaw Hospital
Non-Alcoholic Fatty Liver Disease, Obesity
Bariatric Surgery on NASH
The study investigates non-alcoholic fatty liver disease from serial liver biopsies collected from participants referred for assessment of bariatric surgery, RYGB or SG.
- Trial name
- NCT04043585
- Where
- Denmark
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Hypertriglyceridemia, Nonalcoholic Fatty Liver Disease
Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD
This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of 2 dose levels of TLC-2716 in subjects with hypertriglyceridemia and nonalcoholic fatty liver disease as…
- Trial name
- NCT06564584
- Testing
- TLC-2716 Dose 1, TLC-2716 Dose 2
- Where
- 4 sites in Mexico
- Volunteers
- 30 people
- Sponsor
- OrsoBio, Inc
Metabolic Syndrome, NAFLD
Effects of Short-term Interventions for a Healthy Lifestyle on the Human Lipidome in Subjects With Metabolic Syndrome
A growing number of cross-sectional studies is investigated the role of the human lipidome as a new biomarker for metabolic diseases.
- Conditions
- Metabolic Syndrome, NAFLD, Obesity, Hypertension
- Trial name
- GesundLeben (NCT03047655)
- Testing
- Lifestyle intervention (physical activity), Lifestyle intervention (PUFA/isomaltulose-enriched muffin)
- Where
- 2 sites in Germany
- Volunteers
- 100 people
- Sponsor
- German Institute of Human Nutrition
NASH - Nonalcoholic Steatohepatitis
Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)
This study will assess the effect of 3 doses of PXL065 versus placebo on liver fat content in NASH patients after 36 weeks of treatment
- Trial name
- NCT04321343
- Testing
- PXL065
- Where
- 29 sites in United States
- Volunteers
- 117 people
- Sponsor
- Poxel SA
Steatohepatitis, Nonalcoholic
The Leukotriene Receptor Antagonist Montelukast in the Treatment of Non-alcoholic Steatohepatitis
The aim of the current study is to evaluate the safety and efficay of Montelukast in treatment of patients with fatty liver disease.
- Trial name
- NCT04080947
- Testing
- Control group, Montelukast group
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- Sadat City University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.